Patents by Inventor David Hurwitz

David Hurwitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240279634
    Abstract: Site-specific modification of proteins with microbial transglutaminase (MTG) is a powerful and versatile strategy for a controlled modification of proteins under physiological conditions. We present evidence that solid-phase microbead-immobilization can be used to site-specifically and efficiently attach different functional molecules important for further downstream applications to proteins of therapeutic relevance including scFV, Fab-fragment and antibodies. We demonstrate that MTG remained firmly immobilized with no detectable column bleeding and that enzyme activity was sustained during continuous operation, which allowed for a convenient recycling of the enzyme, thus going beyond solution-phase MTG conjugation. In addition it is showed that immobilized MTG shows enhanced selectivity towards a certain residue in the presence of several reactive residues which are all targeted if the conjugation was carried out in solution.
    Type: Application
    Filed: January 30, 2024
    Publication date: August 22, 2024
    Inventors: Philipp Rene SPYCHER, Martin BEHE, Roger SCHIBLI, David HURWITZ, Olivier KREIS
  • Patent number: 11860114
    Abstract: Atomic position data may be obtained from x-ray diffraction data. The x-ray diffraction data for a sample may be squared and/or otherwise operated on to obtain input data for a neural network. The input data may be input to a trained convolutional neural network. The convolutional neural network may have been trained based on pairs of known atomic structures and corresponding neural network inputs. For the neural network input corresponding to the sample and input to the trained convolutional neural network, the convolutional neural network may obtain an atomic structure corresponding to the sample.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: January 2, 2024
    Inventor: David Hurwitz
  • Publication number: 20220333093
    Abstract: Site-specific modification of proteins with microbial transglutaminase (MTG) is a powerful and versatile strategy for a controlled modification of proteins under physiological conditions. We present evidence that solid-phase microbead-immobilization can be used to site-specifically and efficiently attach different functional molecules important for further downstream applications to proteins of therapeutic relevance including scFV, Fab-fragment and antibodies. We demonstrate that MTG remained firmly immobilized with no detectable column bleeding and that enzyme activity was sustained during continuous operation, which allowed for a convenient recycling of the enzyme, thus going beyond solution-phase MTG conjugation. In addition it is showed that immobilized MTG shows enhanced selectivity towards a certain residue in the presence of several reactive residues which are all targeted if the conjugation was carried out in solution.
    Type: Application
    Filed: March 25, 2022
    Publication date: October 20, 2022
    Inventors: Philipp Rene SPYCHER, Martin BEHE, Roger SCHIBLI, David HURWITZ, Olivier KREIS
  • Patent number: 11396649
    Abstract: Site-specific modification of proteins with microbial transglutaminase (MTG) is a powerful and versatile strategy for a controlled modification of proteins under physiological conditions. Solid-phase microbead-immobilization is used to site-specifically and efficiently attach different functional molecules important for further downstream applications to proteins of therapeutic relevance including scFV, Fab-fragment and antibodies. MTG remained firmly immobilized with no detectable column bleeding and enzyme activity was sustained during continuous operation. Immobilized MTG shows enhanced selectivity towards a certain residue in the presence of several reactive residues which are all targeted when the conjugation was carried out in solution. The generation of dual site-specifically conjugated IgG1 with immobilized and MTG in solution is reported, i.e. site-specific conjugation to glutamine and lysine residues of IgG1 antibody.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: July 26, 2022
    Assignee: PAUL SCHERRER INSTITUT
    Inventors: Philipp Rene Spycher, Martin Behe, Roger Schibli, David Hurwitz, Olivier Kreis
  • Publication number: 20210302332
    Abstract: Atomic position data may be obtained from x-ray diffraction data. The x-ray diffraction data for a sample may be squared and/or otherwise operated on to obtain input data for a neural network. The input data may be input to a trained convolutional neural network. The convolutional neural network may have been trained based on pairs of known atomic structures and corresponding neural network inputs. For the neural network input corresponding to the sample and input to the trained convolutional neural network, the convolutional neural network may obtain an atomic structure corresponding to the sample.
    Type: Application
    Filed: March 26, 2020
    Publication date: September 30, 2021
    Inventor: David HURWITZ
  • Publication number: 20190194641
    Abstract: Site-specific modification of proteins with microbial transglutaminase (MTG) is a powerful and versatile strategy for a controlled modification of proteins under physiological conditions. Solid-phase microbead-immobilization is used to site-specifically and efficiently attach different functional molecules important for further downstream applications to proteins of therapeutic relevance including scFV, Fab-fragment and antibodies. MTG remained firmly immobilized with no detectable column bleeding and enzyme activity was sustained during continuous operation. Immobilized MTG shows enhanced selectivity towards a certain residue in the presence of several reactive residues which are all targeted when the conjugation was carried out in solution. The generation of dual site-specifically conjugated IgG1 with immobilized and MTG in solution is reported, i.e. site-specific conjugation to glutamine and lysine residues of IgG1 antibody.
    Type: Application
    Filed: July 11, 2017
    Publication date: June 27, 2019
    Inventors: PHILIPP RENE SPYCHER, MARTIN BEHE, ROGER SCHIBLI, DAVID HURWITZ
  • Patent number: 9399701
    Abstract: The present invention encompasses polymer compositions comprising aliphatic polycarbonate chains containing sites of olefinic unsaturation. In certain embodiments the aliphatic polycarbonate chains comprise sites of olefinic unsaturation capable of participating in radical-promoted olefin polymerizations. In certain embodiments, the invention encompasses composites formed by the polymerization or cross-linking of a combination of olefinic monomers and aliphatic polycarbonate chains containing sites of olefinic unsaturation.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: July 26, 2016
    Assignee: Novomer, Inc.
    Inventors: Scott D. Allen, Jay J. Farmer, Peter Kopf, David Hurwitz, Thomas R. Welter
  • Publication number: 20130172482
    Abstract: The present invention encompasses polymer compositions comprising aliphatic polycarbonate chains containing sites of olefinic unsaturation. In certain embodiments the aliphatic polycarbonate chains comprise sites of olefinic unsaturation capable of participating in radical-promoted olefin polymerizations. In certain embodiments, the invention encompasses composites formed by the polymerization or cross-linking of a combination of olefinic monomers and aliphatic polycarbonate chains containing sites of olefinic unsaturation.
    Type: Application
    Filed: August 26, 2011
    Publication date: July 4, 2013
    Applicant: NOVOMER, INC.
    Inventors: Scott D. Allen, Jay J. Farmer, Peter Kopf, David Hurwitz, Thomas R. Welter